In a report released today, Laura Sutcliffe from UBS maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a price target of A$19.30. The company’s shares closed yesterday at $8.14.
According to TipRanks, Sutcliffe is a 4-star analyst with an average return of 4.1% and a 58.62% success rate. Sutcliffe covers the Healthcare sector, focusing on stocks such as CSL, Telix Pharmaceuticals Ltd., and Cochlear Limited.
Telix Pharmaceuticals Ltd. has an analyst consensus of Strong Buy, with a price target consensus of $10.14, a 24.57% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a A$15.30 price target.
TLPPF market cap is currently $2.74B and has a P/E ratio of 967.42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Telix Pharmaceuticals Ltd. (TLPPF) Company Description:
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer. Geographically, it operates in Australia, the United States, Belgium, and Japan.
